Drug profile

The FDA adverse-event record for Fatty Acid

81 FDA reports name Fatty Acid, a high-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#867 of 2,679
by report volume (all drugs)
81
adverse-event reports
7.4%
death-coded share
Dog
most-reported species

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Fatty Acid ranks #866 of 2679 by total reports (81) and #673 of 1130 by death-coded share (7.4%). National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#866
This drug, reports of 2679
#673
This drug, death share of 1130

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Fatty Acid has 81 reports now versus 81 in that prior snapshot: 0 the same number of (0.0%).

Report change
+0
Death-coded reports
+0
Death-coded share
+0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Fatty Acid changes

Signature read: 81 reports place Fatty Acid in the upper third of FDA AER volume (#867 of 2,679).

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
81
Total Reports
6
Deaths Reported
7.4%
Death-coded share of reports

Active Ingredients

Fatty Acid

Administration Routes

UnknownOralTopical

Species Affected

Dog 81

Most Affected Breeds

Retriever - Labrador 13
Shih Tzu 4
Mixed (Dog) 3
Terrier - Jack Russell 3
Terrier - West Highland White 3
Pug 3
Schnauzer - Miniature 3
Bulldog - French 3
Dachshund - Standard Long-haired 3
Collie (unspecified) 2

Most Reported Reactions

INEFFECTIVE, LOSS OF EFFECT 22
Lack of efficacy - NOS 14
Other abnormal test result NOS 8
Lethargy (see also Central nervous system depression in 'Neurological') 8
INEFFECTIVE, ATOPY CONTROL 8
Diarrhoea 7
Vomiting 7
Drug administration error 5
Polyuria 4
Fever 4
Elevated serum alkaline phosphatase (SAP) 4
Anorexia 4

Outcome Breakdown

Ongoing
62 (76.5%)
Outcome Unknown
7 (8.6%)
Recovered/Normal
6 (7.4%)
Died
4 (4.9%)
Euthanized
2 (2.5%)

Fatty Acid: high report volume in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

High-volume nationwide drug peers

Two openFDA-derived peer sets for Fatty Acid, both floored at ≥50 reports so the neighborhoods stay in the advertised mass.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Fatty Acid (#867 of 2,679 by report volume); death-coded 7.4%. PlainBreed drug row · report volume stamp 81 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →